PHOENIX — A study presented on Thursday at the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting found that omalizumab eliminated the need for epinephrine in patients with alpha-gal syndrome. The research analyzed 64 patients treated with the drug between April 2022 and November 2025.

During omalizumab therapy, no patients in the study required epinephrine for food-triggered reactions. Before treatment, 53% of the patients had required epinephrine and 81% had experienced anaphylaxis.

"In our study, patients treated with omalizumab had fewer or less severe reactions, and none required epinephrine for a food-related reaction while on therapy," said Collette M. Tilly, MD. She added that 95% of patients reported a clinically meaningful reduction in reaction frequency or severity while taking the medication.

"These findings suggest that omalizumab may offer an additional layer of protection for patients living with alpha-gal syndrome," Tilly said. Thirty-one percent of patients were able to reintroduce some or all mammalian foods or products into their diet while on the therapy, though two patients discontinued treatment due to adverse events.

The meeting also featured a case report describing a 66-year-old man who experienced delayed hives, coughing, and oxygen desaturation after consuming red meat and alcohol. The patient had alpha-gal IgE levels greater than 100 kU/L.

"In this case, even an experienced physician didn’t think of alpha-gal at first, and that happens frequently," said Jeffrey Yu, MS. "On average, people wait about seven years to get the right diagnosis."

Yu noted that the condition carries psychological burdens, with two-thirds of people with alpha-gal syndrome reporting anxiety or depressive disorders and 63% avoiding social situations involving food. "Living with AGS means worrying about every meal," he said. "Patients need mental health support along with good medical care." Alpha-gal syndrome affects an estimated 96,000 to 450,000 Americans, and a 47-year-old man in New Jersey died from the condition in 2025, marking the first documented fatality.